KOD logo

Kodiak Sciences Inc (KOD)

$96.80

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on KOD

Market cap

$6.33B

EPS

-4.08

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.018365

Price on KOD

Previous close

$100.73

Today's open

$101.74

Day's range

$94.62 - $104.36

52 week range

$18.15 - $112.79

Profile about KOD

CEO

Victor Perlroth

Employees

141

Headquarters

Palo Alto, CA

Exchange

NASDAQ Global Market

Shares outstanding

65395553

Issue type

Common Stock

KOD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on KOD

Kodiak Sciences Inc. (KOD) Presents at UBS Global Biopharma Conference 2026 Transcript

Kodiak Sciences Inc. ( KOD ) UBS Global Biopharma Conference 2026 November 17, 2026 4:20 AM EST Company Participants Victor Perlroth - Co-Founder, Chairman, CEO & President Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division All right. Well, good morning, everyone.

news source

Seeking Alpha • Nov 17, 2026

news preview

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced In

Kodiak Sciences Inc. is up 1,857% since my November 2024 Hold upgrade; I maintain Hold as its ~$6.8 billion valuation embeds optimistic commercial expectations. Zenkuda's multi-indication BLA submission is set to begin in Q4, with standard FDA review potentially yielding approval in late 2027 or early 2028. KOD's twice-yearly diabetic retinopathy dosing is compelling, but biosimilars and established brands limit penetration; switching well-controlled patients will be difficult.

news source

Seeking Alpha • Nov 13, 2026

news preview

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results

PALO ALTO, Calif., Nov. 12, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2026.

news source

PRNewsWire • Nov 12, 2026

news preview

Kodiak Sciences to Present at Three Upcoming Investor Conferences

PALO ALTO, Calif., Nov. 11, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.

news source

PRNewsWire • Nov 11, 2026

news preview

Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review

The top contributors to the Portfolio's relative performance in the quarter were Kodiak Sciences, Flotek Industries, and Hyperliquid Strategies. The most significant detractors from the Portfolio's relative performance in the quarter were Vishay Precision Group, Babcock & Wilcox, and CareDx (not held). The salient changes to positioning this quarter included our increased exposure to Health Care and decreased exposure to Industrials.

news source

Seeking Alpha • Nov 4, 2026

news preview

Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.

news source

Zacks Investment Research • Oct 19, 2026

news preview

11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

news source

Schaeffers Research • Oct 12, 2026

news preview

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).

news source

PRNewsWire • Oct 7, 2026

news preview

Top 3 Health Care Stocks That May Collapse In Q4

As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

news source

Benzinga • Oct 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Kodiak Sciences Inc

Open an M1 investment account to buy and sell Kodiak Sciences Inc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in KOD on M1